Drugs / Eltanexor
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06399640 | Aug 2024 → Feb 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Vanderbilt-Ingram Cancer Center | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05918055 | Nov 2023 → Mar 2025 | myelodysplastic syndrome | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT02649790 | Jan 2016 → Aug 2024 | acute myeloid leukemia, castration-resistant prostate carcinoma, colorectal cancer, myelodysplastic syndrome +1 | Karyopharm Therapeutics Inc | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eltanexor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06399640 ↗ |
| Known as | KPT-8602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02649790 ↗ |
| Action | Inhibit | “the second generation oral XPO1 inhibitor KPT-8602” NCT02649790 ↗ |
| Modality | Small molecule | — CHEMBL4297623 ↗ |
| Route | Oral | “Participants will receive KPT-8602 oral tablets.” NCT02649790 ↗ |
| Target | XPO1 | “the second generation oral XPO1 inhibitor KPT-8602” NCT02649790 ↗ |